Focused On-demand Library for Kinesin-like protein KIF20B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96Q89

UPID:

KI20B_HUMAN

Alternative names:

Cancer/testis antigen 90; Kinesin family member 20B; Kinesin-related motor interacting with PIN1; M-phase phosphoprotein 1

Alternative UPACC:

Q96Q89; A8MXM7; O43277; Q09471; Q2KQ73; Q32NE1; Q561V3; Q58EX8; Q5T9M8; Q5T9M9; Q5T9N0; Q5T9N1; Q7KZ68; Q7Z5E0; Q7Z5E1; Q7Z6M9; Q86X82; Q9H3R8; Q9H6Q9; Q9H755; Q9NTC1; Q9UFR5

Background:

Kinesin-like protein KIF20B, also known as Cancer/testis antigen 90 and M-phase phosphoprotein 1, plays a pivotal role in cell division by mediating cytokinesis. It is essential for midbody organization and abscission in polarized cortical stem cells. Furthermore, KIF20B is involved in neuronal polarization, facilitating the transport of specific cargos for the development of the cerebral cortex. Its function extends to promoting the transition from multipolar to bipolar stages and radial migration of cortical neurons, highlighting its significance in brain development.

Therapeutic significance:

Given its role in cell division and neuronal development, KIF20B's involvement in bladder cancer proliferation and progression underscores its potential as a therapeutic target. Understanding the role of Kinesin-like protein KIF20B could open doors to potential therapeutic strategies, especially in oncology, by targeting its function to inhibit cancer cell proliferation and promote apoptosis.